Overview
“Without going so far as to speak of euphoria at this stage, the biotechnology sector has seen a succession of major mergers and acquisitions since the beginning of the year, reflecting the desire of major pharmaceutical companies to strengthen their pipeline. Jeito Capital, a biopharmaceutical fund based in France, is part of this trend.”
Click here to read Anthony Paronneau’s commentary on this trend in Wansquare.
